CN116087486B - Biomarkers for early prediction of cardiovascular disease (CVD) in diabetics and uses thereof - Google Patents
Biomarkers for early prediction of cardiovascular disease (CVD) in diabetics and uses thereof Download PDFInfo
- Publication number
- CN116087486B CN116087486B CN202211510557.0A CN202211510557A CN116087486B CN 116087486 B CN116087486 B CN 116087486B CN 202211510557 A CN202211510557 A CN 202211510557A CN 116087486 B CN116087486 B CN 116087486B
- Authority
- CN
- China
- Prior art keywords
- cvd
- biomarker
- samples
- ndm
- diabetes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000024172 Cardiovascular disease Diseases 0.000 title claims abstract description 323
- 239000000090 biomarker Substances 0.000 title claims abstract description 180
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 204
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 34
- 239000012472 biological sample Substances 0.000 claims abstract description 16
- 238000002360 preparation method Methods 0.000 claims abstract description 6
- RWKUXQNLWDTSLO-GWQJGLRPSA-N N-hexadecanoylsphingosine-1-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)[C@H](O)\C=C\CCCCCCCCCCCCC RWKUXQNLWDTSLO-GWQJGLRPSA-N 0.000 claims description 35
- 210000004369 blood Anatomy 0.000 claims description 20
- 239000008280 blood Substances 0.000 claims description 20
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 15
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 12
- 238000004587 chromatography analysis Methods 0.000 claims description 8
- 238000004811 liquid chromatography Methods 0.000 claims description 8
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 6
- 235000019253 formic acid Nutrition 0.000 claims description 6
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 claims description 5
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 claims description 3
- 239000005695 Ammonium acetate Substances 0.000 claims description 3
- 235000019257 ammonium acetate Nutrition 0.000 claims description 3
- 229940043376 ammonium acetate Drugs 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 230000007211 cardiovascular event Effects 0.000 abstract description 22
- 230000001154 acute effect Effects 0.000 abstract description 11
- 206010007556 Cardiac failure acute Diseases 0.000 abstract description 8
- 206010042434 Sudden death Diseases 0.000 abstract description 8
- 206010008118 cerebral infarction Diseases 0.000 abstract description 8
- 208000026106 cerebrovascular disease Diseases 0.000 abstract description 8
- 206010000891 acute myocardial infarction Diseases 0.000 abstract description 6
- 210000002381 plasma Anatomy 0.000 description 67
- 238000000034 method Methods 0.000 description 57
- 239000000523 sample Substances 0.000 description 53
- 238000001514 detection method Methods 0.000 description 43
- 239000008777 Glycerylphosphorylcholine Substances 0.000 description 39
- SUHOQUVVVLNYQR-MRVPVSSYSA-N choline alfoscerate Chemical compound C[N+](C)(C)CCOP([O-])(=O)OC[C@H](O)CO SUHOQUVVVLNYQR-MRVPVSSYSA-N 0.000 description 39
- 238000002474 experimental method Methods 0.000 description 39
- 150000002316 glycerophosphocholines Chemical class 0.000 description 39
- 229960004956 glycerylphosphorylcholine Drugs 0.000 description 39
- 238000004458 analytical method Methods 0.000 description 38
- 239000002207 metabolite Substances 0.000 description 37
- 230000001019 normoglycemic effect Effects 0.000 description 34
- JKLRIMRKZBSSED-UHFFFAOYSA-N taurocyamine Chemical compound NC(=[NH2+])NCCS([O-])(=O)=O JKLRIMRKZBSSED-UHFFFAOYSA-N 0.000 description 31
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 21
- 150000001982 diacylglycerols Chemical class 0.000 description 21
- 239000008103 glucose Substances 0.000 description 21
- -1 stearoyl phosphatidylinositol Chemical class 0.000 description 21
- 238000012795 verification Methods 0.000 description 20
- 150000002500 ions Chemical class 0.000 description 19
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 19
- FNPHNLNTJNMAEE-HSZRJFAPSA-N O-octadecanoyl-L-carnitine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C FNPHNLNTJNMAEE-HSZRJFAPSA-N 0.000 description 17
- 238000000605 extraction Methods 0.000 description 17
- GNGACRATGGDKBX-UHFFFAOYSA-L glycerone phosphate(2-) Chemical group OCC(=O)COP([O-])([O-])=O GNGACRATGGDKBX-UHFFFAOYSA-L 0.000 description 17
- GNGACRATGGDKBX-UHFFFAOYSA-N Dihydroxyacetone phosphate Natural products OCC(=O)COP(O)(O)=O GNGACRATGGDKBX-UHFFFAOYSA-N 0.000 description 16
- KXXLFCAPKGRXBT-FMJYHZMHSA-N PC(20:0/18:2(9Z,12Z)) Chemical compound CCCCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC KXXLFCAPKGRXBT-FMJYHZMHSA-N 0.000 description 15
- 238000013211 curve analysis Methods 0.000 description 14
- KNWHKVBHCLQVFX-QXWNENIHSA-N Lactosylceramide (d18:1/12:0) Chemical compound O[C@@H]1C(O)[C@H](OC[C@@H]([C@H](O)/C=C/CCCCCCCCCCCCC)NC(=O)CCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KNWHKVBHCLQVFX-QXWNENIHSA-N 0.000 description 13
- 239000000126 substance Substances 0.000 description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 239000013068 control sample Substances 0.000 description 12
- 230000002503 metabolic effect Effects 0.000 description 12
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 11
- 229940106189 ceramide Drugs 0.000 description 11
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 11
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 11
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 10
- 238000000513 principal component analysis Methods 0.000 description 10
- 239000003643 water by type Substances 0.000 description 10
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 239000008101 lactose Substances 0.000 description 9
- LRYZPFWEZHSTHD-HEFFAWAOSA-O 2-[[(e,2s,3r)-2-formamido-3-hydroxyoctadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium Chemical class CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](NC=O)COP(O)(=O)OCC[N+](C)(C)C LRYZPFWEZHSTHD-HEFFAWAOSA-O 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 238000012216 screening Methods 0.000 description 8
- VODZWWMEJITOND-NXCSZAMKSA-N N-octadecanoylsphingosine Chemical compound CCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)\C=C\CCCCCCCCCCCCC VODZWWMEJITOND-NXCSZAMKSA-N 0.000 description 7
- XOAAWQZATWQOTB-UHFFFAOYSA-N Taurine Natural products NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 150000002305 glucosylceramides Chemical class 0.000 description 7
- 238000004949 mass spectrometry Methods 0.000 description 7
- 230000004060 metabolic process Effects 0.000 description 7
- 238000004611 spectroscopical analysis Methods 0.000 description 7
- 238000012418 validation experiment Methods 0.000 description 7
- 206010019280 Heart failures Diseases 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 201000001421 hyperglycemia Diseases 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 238000007619 statistical method Methods 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- WAHOQVZGGPERKB-UHFFFAOYSA-N 1,1-dihydroxypropan-2-one phosphoric acid Chemical compound P(=O)(O)(O)O.OC(C(C)=O)O.P(=O)(O)(O)O.OC(C(C)=O)O WAHOQVZGGPERKB-UHFFFAOYSA-N 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 4
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 4
- 238000004817 gas chromatography Methods 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 208000010125 myocardial infarction Diseases 0.000 description 4
- 229940104261 taurate Drugs 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 208000013600 Diabetic vascular disease Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 201000009101 diabetic angiopathy Diseases 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- XPFVYQJUAUNWIW-UHFFFAOYSA-N furfuryl alcohol Chemical compound OCC1=CC=CO1 XPFVYQJUAUNWIW-UHFFFAOYSA-N 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 238000010239 partial least squares discriminant analysis Methods 0.000 description 3
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000012086 standard solution Substances 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- JLIDBLDQVAYHNE-YKALOCIXSA-N (+)-Abscisic acid Chemical compound OC(=O)/C=C(/C)\C=C\[C@@]1(O)C(C)=CC(=O)CC1(C)C JLIDBLDQVAYHNE-YKALOCIXSA-N 0.000 description 2
- YVLPJIGOMTXXLP-UHFFFAOYSA-N 15-cis-phytoene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC(C)=CC=CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C YVLPJIGOMTXXLP-UHFFFAOYSA-N 0.000 description 2
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
- WSGYTJNNHPZFKR-UHFFFAOYSA-N 3-hydroxypropanenitrile Chemical compound OCCC#N WSGYTJNNHPZFKR-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- HGINCPLSRVDWNT-UHFFFAOYSA-N Acrolein Chemical compound C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 description 2
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N Butyraldehyde Chemical compound CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 description 2
- 208000031229 Cardiomyopathies Diseases 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 208000032382 Ischaemic stroke Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 208000005764 Peripheral Arterial Disease Diseases 0.000 description 2
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 238000000149 argon plasma sintering Methods 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 229940104302 cytosine Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000012921 fluorescence analysis Methods 0.000 description 2
- 238000005558 fluorometry Methods 0.000 description 2
- HYBBIBNJHNGZAN-UHFFFAOYSA-N furfural Chemical compound O=CC1=CC=CO1 HYBBIBNJHNGZAN-UHFFFAOYSA-N 0.000 description 2
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 238000004848 nephelometry Methods 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000007781 pre-processing Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000004088 pulmonary circulation Effects 0.000 description 2
- 238000005514 radiochemical analysis Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 229960003080 taurine Drugs 0.000 description 2
- 150000003505 terpenes Chemical class 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- RVOXBKZHFYRXCD-QKKXKWKRSA-N (2s,3r,4s,5r,6r)-2-[(2r,3s,4r,5r)-6-amino-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)C(N)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 RVOXBKZHFYRXCD-QKKXKWKRSA-N 0.000 description 1
- 239000001707 (E,7R,11R)-3,7,11,15-tetramethylhexadec-2-en-1-ol Substances 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- YVLPJIGOMTXXLP-UUKUAVTLSA-N 15,15'-cis-Phytoene Natural products C(=C\C=C/C=C(\CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)/C)(\CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)/C YVLPJIGOMTXXLP-UUKUAVTLSA-N 0.000 description 1
- YVLPJIGOMTXXLP-BAHRDPFUSA-N 15Z-phytoene Natural products CC(=CCCC(=CCCC(=CCCC(=CC=C/C=C(C)/CCC=C(/C)CCC=C(/C)CCC=C(C)C)C)C)C)C YVLPJIGOMTXXLP-BAHRDPFUSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 101100519158 Arabidopsis thaliana PCR2 gene Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 206010007558 Cardiac failure chronic Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010017472 Fumbling Diseases 0.000 description 1
- 229930191978 Gibberellin Natural products 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 206010058558 Hypoperfusion Diseases 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- FAIXYKHYOGVFKA-UHFFFAOYSA-N Kinetin Natural products N=1C=NC=2N=CNC=2C=1N(C)C1=CC=CO1 FAIXYKHYOGVFKA-UHFFFAOYSA-N 0.000 description 1
- 206010024119 Left ventricular failure Diseases 0.000 description 1
- 108010022337 Leucine Enkephalin Proteins 0.000 description 1
- 241000721701 Lynx Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- BLUHKGOSFDHHGX-UHFFFAOYSA-N Phytol Natural products CC(C)CCCC(C)CCCC(C)CCCC(C)C=CO BLUHKGOSFDHHGX-UHFFFAOYSA-N 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- MEFKEPWMEQBLKI-AIRLBKTGSA-O S-adenosyl-L-methionine Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H]([NH3+])C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-O 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- HNZBNQYXWOLKBA-UHFFFAOYSA-N Tetrahydrofarnesol Natural products CC(C)CCCC(C)CCCC(C)=CCO HNZBNQYXWOLKBA-UHFFFAOYSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 1
- XBJFCYDKBDVADW-UHFFFAOYSA-N acetonitrile;formic acid Chemical compound CC#N.OC=O XBJFCYDKBDVADW-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- BOTWFXYSPFMFNR-OALUTQOASA-N all-rac-phytol Natural products CC(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)=CCO BOTWFXYSPFMFNR-OALUTQOASA-N 0.000 description 1
- 150000001409 amidines Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 239000003150 biochemical marker Substances 0.000 description 1
- 230000007321 biological mechanism Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 206010007625 cardiogenic shock Diseases 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Natural products C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 239000002989 correction material Substances 0.000 description 1
- 210000002726 cyst fluid Anatomy 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- FCRACOPGPMPSHN-UHFFFAOYSA-N desoxyabscisic acid Natural products OC(=O)C=C(C)C=CC1C(C)=CC(=O)CC1(C)C FCRACOPGPMPSHN-UHFFFAOYSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000001610 euglycemic effect Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- IXORZMNAPKEEDV-UHFFFAOYSA-N gibberellic acid GA3 Natural products OC(=O)C1C2(C3)CC(=C)C3(O)CCC2C2(C=CC3O)C1C3(C)C(=O)O2 IXORZMNAPKEEDV-UHFFFAOYSA-N 0.000 description 1
- 239000003448 gibberellin Substances 0.000 description 1
- 229940015043 glyoxal Drugs 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000005986 heart dysfunction Effects 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000004047 hole gas Substances 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 150000004715 keto acids Chemical class 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- QANMHLXAZMSUEX-UHFFFAOYSA-N kinetin Chemical compound N=1C=NC=2N=CNC=2C=1NCC1=CC=CO1 QANMHLXAZMSUEX-UHFFFAOYSA-N 0.000 description 1
- 229960001669 kinetin Drugs 0.000 description 1
- 150000002596 lactones Chemical group 0.000 description 1
- URLZCHNOLZSCCA-UHFFFAOYSA-N leu-enkephalin Chemical compound C=1C=C(O)C=CC=1CC(N)C(=O)NCC(=O)NCC(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=CC=C1 URLZCHNOLZSCCA-UHFFFAOYSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 238000002705 metabolomic analysis Methods 0.000 description 1
- 230000001431 metabolomic effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- INAXVFBXDYWQFN-XHSDSOJGSA-N morphinan Chemical class C1C2=CC=CC=C2[C@]23CCCC[C@H]3[C@@H]1NCC2 INAXVFBXDYWQFN-XHSDSOJGSA-N 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 238000003909 pattern recognition Methods 0.000 description 1
- 230000003836 peripheral circulation Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 235000011765 phytoene Nutrition 0.000 description 1
- BOTWFXYSPFMFNR-PYDDKJGSSA-N phytol Chemical compound CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC\C(C)=C\CO BOTWFXYSPFMFNR-PYDDKJGSSA-N 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 239000012521 purified sample Substances 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 150000004053 quinones Chemical class 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 210000004895 subcellular structure Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 150000003628 tricarboxylic acids Chemical class 0.000 description 1
- 150000004043 trisaccharides Chemical class 0.000 description 1
- 238000001195 ultra high performance liquid chromatography Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- HGBOYTHUEUWSSQ-UHFFFAOYSA-N valeric aldehyde Natural products CCCCC=O HGBOYTHUEUWSSQ-UHFFFAOYSA-N 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The present application relates to a kit for predicting whether a subject suffers from a cardiovascular disease, in particular a cardiovascular event, and the use of a reagent for determining biomarker levels in a biological sample in the preparation of a kit. The biomarkers of the present application can be used to predict cardiovascular disease, particularly cardiovascular event (e.g., acute myocardial infarction, acute heart failure, acute cerebral infarction, and sudden death) risk in a subject (e.g., a subject with diabetes).
Description
The divisional application is based on the original Chinese patent application with the application number of CN202111315640.8, the application date of 2021, 11 months and 8 days, and the invention name of biomarker for early prediction of cardiovascular disease (CVD) of diabetics and application thereof.
Technical Field
The present application relates to the field of medicine. The present application relates in particular to a kit for predicting whether a diabetic subject is at risk of suffering from a cardiovascular disease, in particular a cardiovascular event, and to the use of a reagent for determining the level of a biomarker in a biological sample in the preparation of a kit.
Background
Diabetes is a major chronic disease that is a hazard to human health. Diabetic patients have a higher, earlier risk of developing cardiovascular disease (CVD) than non-diabetic patients, and the risk of mortality is also increased by a factor of 2-4. At present, the exact molecular biological mechanism of diabetes for promoting the occurrence of cardiovascular diseases is not clear, and early and effective prediction of the cardiovascular disease risk of a diabetes patient group is difficult.
Early warning of diabetes complicated with cardiovascular and cerebrovascular diseases risks can most effectively apply limited medical resources to high risk groups of cardiovascular diseases, and accurate treatment is achieved. Previous studies have shown that lipid intracellular acyl carnitine is associated with CVD risk. In prospective cohort studies and case cohort studies, the lipidomic profile and plasma choline pathway metabolites are associated with major cardiovascular events. However, there has been no report of related metabolites that predict early stages of cardiovascular disease, particularly cardiovascular events, in diabetes.
The high performance liquid chromatography tandem mass spectrometry detection technology is characterized in that liquid chromatography and mass spectrometry are connected in series, the relative molecular mass and structural information of metabolites are provided while different polar components of a sample are separated, and the method is suitable for analysis and determination of trace and trace substances in a complex biological system, and has the characteristics of high sensitivity, high separation efficiency, high analysis speed, no influence of sample volatility and stability and the like.
The method utilizes factors other than traditional risk factors to predict cardiovascular diseases, especially cardiovascular event risks, improves the capability of early predicting cardiovascular high risk groups, and is particularly important to early warn the high risk groups to provide early intervention.
Disclosure of Invention
Through extensive experimentation and repeated fumbling, the inventors of the present application have obtained biomarkers that can be used as markers for characterizing hyperglycemia-related cardiovascular diseases, in particular cardiovascular events, by analysis of 4 different sets of samples. Thus, the biomarkers of the present application are useful for predicting cardiovascular disease, particularly the risk of cardiovascular events, in diabetics.
Thus, in a first aspect, the present application provides the use of an agent for determining the level of a biomarker in a biological sample in the manufacture of a kit for predicting whether a subject suffering from diabetes is at risk for a cardiovascular disease, in particular a cardiovascular event; wherein the biomarker is selected from dihydroxyacetone phosphate (Dihydroxyacetone phosphate), guanyl taurine (Taurocyamine), lactose ceramide (d18:1/12:0) (lactosyerceramide (d18:1/12:0)), glycerophosphorylcholine (18:1/18:1) (Glycerophosphocholines PC (18:1/18:1)), palmitoyl sphingomyelin (Palmitoyl sphingomyelin), glycerophosphorylcholine (20:0/18:2) (Glycerophosphocholines PC (20:0/18:2)), diglycerides (22:1 n9/0:0/22:6n 3) (Diacylglycerol DAG (22:1 n9/0:0/22:6n 3)), glycerophosphorylcholine (24:1/14:0) (Glycerophosphocholines PC (24:1/14:0)), glucose ceramide (d18:1/18:0)), glycerophosphorylcholine (18:4/24:1/2) (Diacylglycerol DAG:564/24:1/24), stearoyl phosphatidylinositol (24:1/12:1), stearoyl phosphatidylinositol (24:1/6 n 3), or any combination thereof.
Specifically, the CAS number of the dihydroxyacetone phosphate (Dihydroxyacetone phosphate) is CAS 10030-20-3; the CAS number of the amidino taurine (Taurocyamine) is CAS 543-18-0; the CAS number of lactose ceramide (d18:1/12:0) (Lactosylate (d18:1/12:0)) is CAS number 474943-80-1; the HMDB ID number of the glycerophosphorylcholine (18:1/18:1) (Glycerophosphocholines PC (18:1/18:1)) is HMDB:0008103; the CAS number of the palmitoyl sphingomyelin (Palmitoyl sphingomyelin) is CAS 6254-89-3; the HMDB ID number of the glycerophosphorylcholine (20:0/18:2) (Glycerophosphocholines PC (20:0/18:2)) is HMDB:0008270; the diglyceride (22:1n9/0:0/22:6n3) (Diacylglycerol DAG (22:1n9/0:0/22:6n3)) has an HMDB ID number of HMDB0056266; the HMDB ID number of the glycerophosphorylcholine (24:1/14:0) (Glycerophosphocholines PC (24:1/14:0)) is HMDB:0008788; the CAS number of the Glucosylceramide (d18:1/18:0) (glucopyranosyl ceramide (d18:1/18:0)) is CAS number 85305-87-9; the diglyceride (18:4/24:1/0:0) (Diacylglycerol DAG (18:4/24:1/0:0)) has an HMDB ID number of HMDB:0007355; the CAS number of the sphingomyelin (d18:1/24:1) (sphingomyelins SM (d18:1/24:1)) is CAS 94359-13-4; the CAS number of the 1-stearoyl phosphatidylinositol (1-stearoyl phosphatidylinositol) is CAS (CAS: 327620-46-2); the CAS number of stearoyl carnitine (stearoyl carnitine) is CAS 25597-09-5.
In another aspect, the present application provides a method for predicting whether a subject suffering from diabetes is at risk of a cardiovascular disease, in particular a cardiovascular event, the method comprising:
(1) Detecting the level of a biomarker in a biological sample from the subject, wherein the biomarker is selected from dihydroxyacetone phosphate (Dihydroxyacetone phosphate), guanyl taurate (taurocyanine), lactose ceramide (d 18:1/12:0)) (lactosylynamide (d 18:1/12:0)), glycerophosphorylcholine (18:1/18:1) (Glycerophosphocholines PC (18:1/18:1)), palmitoyl sphingomyelin (Palmitoyl sphingomyelin), glycerophosphorylcholine (20:0/18:2) (Glycerophosphocholines PC (20:0/18:2)), diglyceride (22:1 n9/0:0/22:6n 3) (Diacylglycerol DAG (22:1 n9/0:0/22:6n 3)), glycerophosphorylcholine (24:1/14:0) (Glycerophosphocholines PC (24:1/14:0)), glucose ceramide (d 18:1/18:0) (glyceroglycoside (d 18:1/18:0)), glycerophosphorylcholine (18:4/24:4/24:561), stearoyl phosphatidylcholine (24:1/24:2), stearoyl phosphatidylinositol (24:1/2), stearoyl phosphatidylinositol (24:1/3), stearoyl phosphatidyl (24:1/2), stearoyl phosphatidyl (2), stearoyl cholesterol (d 1/6:1/6:1:3);
(2) Comparing the level of the biomarker in the biological sample of the subject with the level of the corresponding biomarker in a control sample, wherein an alteration in the level of the biomarker is capable of being a predictor that the subject is at risk for cardiovascular disease, particularly cardiovascular events.
In certain embodiments, an increase in the level of a biomarker selected from dihydroxyacetone phosphate (Dihydroxyacetone phosphate), lactose ceramide (d 18:1/12:0) (Lactosylceramide (d 18:1/12:0)), glycerophosphorylcholine (18:1/18:1) (Glycerophosphocholines PC (18:1/18:1)), palmitoyl sphingomyelin (Palmitoyl sphingomyelin), glycerophosphorylcholine (20:0/18:2) (Glycerophosphocholines PC (20:0/18:2)), diglycerides (22:1 n9/0:0/22:6n 3) (Diacylglycerol DAG (22:1 n9/0:0/22:6n 3)), glycerophosphorylcholine (24:1/14:0) (Glycerophosphocholines PC (24:1/14:0)), glucose ceramide (d 18:1/18:0) (glyceroglycol (18:1/18:1) (Glycerophosphocholines PC (18:1/18:1)), stearoyl phosphatidylcholine (20:0/18:2) (Glycerophosphocholines PC (20:0/18:2)), stearoyl phosphatidylcholine (22:1/24:1/14:2)), stearoyl phosphatidylcholine (24:1/14:2), and the like, as an indicator of the risk of cardiovascular disease, particularly cardiovascular event, in the subject, compared to the level of the biomarker in a control sample.
In certain embodiments, a decrease in the level of a biomarker selected from the group consisting of guanyltaurine (Taurocyamine) in the subject as compared to the level of the biomarker in a control sample can be used as an indicator of predicting the risk of the subject having a cardiovascular disease.
In certain embodiments, the cardiovascular disease is selected from coronary heart disease, ischemic stroke, peripheral arterial disease, or heart failure; the cardiovascular event is selected from acute myocardial infarction, acute heart failure, acute cerebral infarction, and sudden death; and, the diabetes is a related disease caused by hyperglycemia, such as type 1 diabetes and type 2 diabetes.
In certain embodiments, the cardiovascular event refers to the first occurrence of fatal or non-fatal myocardial infarction, fatal or non-fatal stroke, congestive heart failure hospitalization, or sudden death.
In certain embodiments, the biomarker is selected from the group consisting of any one or a combination of more of the following groups (1) to (7):
(1) Glycerophosphorylcholine (18:1/18:1) (Glycerophosphocholines PC (18:1/18:1)), glycerophosphorylcholine (20:0/18:2) (Glycerophosphocholines PC (20:0/18:2)), and glycerophosphorylcholine (24:1/14:0) (Glycerophosphocholines PC (24:1/14:0));
(2) Palmitoyl sphingomyelin (Palmitoyl sphingomyelin) and sphingomyelin (d18:1/24:1) (sphingomyelins SM (d18:1/24:1));
(3) Diglycerides (22:1n9/0:0/22:6n3) (Diacylglycerol DAG (22:1n9/0:0/22:6n3)) and diglycerides (18:4/24:1/0:0) (Diacylglycerol DAG (18:4/24:1/0:0));
(4) Lactose ceramide (d18:1/12:0) (Lactosylceramide (d18:1/12:0)) and glucose ceramide (d18:1/18:0) (glucosyl ceramide (d18:1/18:0));
(5) Dihydroxyacetone phosphate (Dihydroxyacetone phosphate);
(6) Guanyl taurate (Taurocyamine);
(7) 1-stearoyl phosphatidylinositol (1-stearoyl glycidoxyphosphoinositol) and stearoyl carnitine (stearoyl carnitine).
In certain embodiments, the biological sample is selected from whole blood, serum, plasma, or any combination thereof obtained from a subject.
In certain embodiments, the subject is a mammal, e.g., a human.
In certain embodiments, wherein the reagent (e.g., first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, and/or thirteenth reagent or combination of reagents) determines the level of a biomarker in the biological sample by: chromatographic and/or mass spectrometry, fluorometry, electrophoresis, immunoaffinity, hybridization, immunochemistry, ultraviolet (UV) spectroscopy, fluorescence analysis, radiochemical analysis, near infrared (near IR) spectroscopy, nuclear magnetic resonance spectroscopy (NMR), light scattering analysis (LS) and nephelometry.
In certain embodiments, the reagent determines the level of the biomarker in the biological sample by spectroscopy, liquid or gas chromatography, mass spectrometry, liquid or gas chromatography coupled with mass spectrometry.
In certain embodiments, the kit further comprises reagents and/or consumables for chromatography (e.g., liquid chromatography).
In certain embodiments, the reagents and/or consumables for chromatography are selected from a chromatographic column, an aqueous acetonitrile solution, ammonium acetate, ammonium formate, formic acid, or any combination thereof.
In another aspect, the present application provides a kit for predicting whether a subject suffering from diabetes has a cardiovascular disease, in particular a cardiovascular event, comprising reagents for determining the level of a biomarker selected from dihydroxyacetone phosphate (Dihydroxyacetone phosphate), guanyl taurine (taurocyanine), lactose ceramide (d18:1/12:0) (Lactosylceramide (d 18:1/12:0)), glycerophosphorylcholine (18:1/18:1) (Glycerophosphocholines PC (18:1/18:1)), palmitoyl sphingomyelin (Palmitoyl sphingomyelin), glycerophosphorylcholine (20:0/18:2) (Glycerophosphocholines PC (20:0/18:2)), diglycerides (22:1 n9/0:0/22:6n 3) (Diacylglycerol DAG (22:1 n9/0:0/22:6n 3)), glycerophosphorylcholine (24:1/14:0) (Glycerophosphocholines PC (24:1/14:0) (glycoceramide (d 18:1/18:1:1)), glycerophosphorylcholine (20:0/18:2) (Glycerophosphocholines PC (20:0/18:2)), stearoyl phosphatidylcholine (24:1/18:2) (35:1/14:2), stearoyl phosphatidylinositol (24:24:1/2), stearoyl phosphatidylinositol (24:24:1/18:1), or any combination thereof in a biological sample from the subject.
In certain embodiments, the cardiovascular disease is selected from coronary heart disease, ischemic stroke, peripheral arterial disease, or heart failure; the cardiovascular event is selected from acute myocardial infarction, acute heart failure, acute cerebral infarction, and sudden death; and, the diabetes is a related disease caused by hyperglycemia, such as type 1 diabetes and type 2 diabetes.
In certain embodiments, the cardiovascular event refers to the first occurrence of fatal or non-fatal myocardial infarction, fatal or non-fatal stroke, congestive heart failure hospitalization, or sudden death.
In certain embodiments, the biomarker is selected from the group consisting of any one or a combination of more of the following groups (1) to (7):
(1) Glycerophosphorylcholine (18:1/18:1) (Glycerophosphocholines PC (18:1/18:1)), glycerophosphorylcholine (20:0/18:2) (Glycerophosphocholines PC (20:0/18:2)), and glycerophosphorylcholine (24:1/14:0) (Glycerophosphocholines PC (24:1/14:0));
(2) Palmitoyl sphingomyelin (Palmitoyl sphingomyelin) and sphingomyelin (d18:1/24:1) (sphingomyelins SM (d18:1/24:1));
(3) Diglycerides (22:1n9/0:0/22:6n3) (Diacylglycerol DAG (22:1n9/0:0/22:6n3)) and diglycerides (18:4/24:1/0:0) (Diacylglycerol DAG (18:4/24:1/0:0));
(4) Lactose ceramide (d18:1/12:0) (Lactosylceramide (d18:1/12:0)) and glucose ceramide (d18:1/18:0) (glucosyl ceramide (d18:1/18:0));
(5) Dihydroxyacetone phosphate (Dihydroxyacetone phosphate);
(6) Guanyl taurate (Taurocyamine);
(7) 1-stearoyl phosphatidylinositol (1-stearoyl glycidoxyphosphoinositol) and stearoyl carnitine (stearoyl carnitine).
In certain embodiments, the biological sample is selected from whole blood, serum, plasma, or any combination thereof obtained from a subject.
In certain embodiments, the subject is a mammal, e.g., a human.
In certain embodiments, wherein the reagent (e.g., first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, and/or thirteenth reagent or combination of reagents) determines the level of a biomarker in the biological sample by: chromatographic and/or mass spectrometry, fluorometry, electrophoresis, immunoaffinity, hybridization, immunochemistry, ultraviolet (UV) spectroscopy, fluorescence analysis, radiochemical analysis, near infrared (near IR) spectroscopy, nuclear magnetic resonance spectroscopy (NMR), light scattering analysis (LS) and nephelometry.
In certain embodiments, the reagent determines the level of the biomarker in the biological sample by spectroscopy, liquid or gas chromatography, mass spectrometry, liquid or gas chromatography coupled with mass spectrometry.
In certain embodiments, the kit further comprises reagents and/or consumables for chromatography (e.g., liquid chromatography).
In certain embodiments, the reagents and/or consumables for chromatography are selected from a chromatographic column, an aqueous acetonitrile solution, ammonium acetate, ammonium formate, formic acid, or any combination thereof.
Definition of terms
In the present invention, unless otherwise indicated, scientific and technical terms used herein have the meanings commonly understood by one of ordinary skill in the art. Further, the procedures of molecular genetics, nucleic acid chemistry, molecular biology, biochemistry, cell culture, microbiology, cell biology, genomics and recombinant DNA, etc., as used herein, are all conventional procedures widely used in the corresponding field. Meanwhile, in order to better understand the present invention, definitions and explanations of related terms are provided below.
As used herein, the term "Biomarker" refers to a biochemical marker that can label systems, organs, tissues, cells, and subcellular structures or alterations thereof, with very broad utility. Biomarkers can be used for prediction of disease risk, for judging disease stage or for evaluating the safety and effectiveness of new drugs or new therapies in a target population.
As used herein, the term "metabolite" or "metabolite" refers to a substance produced during the human chemical or physical process. It includes any chemical or biochemical product of a metabolic process, such as any compound produced by processing, cleavage or consumption of biomolecules. Such molecules include, but are not limited to: acids and related compounds; mono-, di-and tricarboxylic acids (saturated, unsaturated aliphatic, aryl, alkylaryl); aldehyde acids and keto acids; a lactone form; gibberellin; abscisic acid; alcohols, polyols, derivatives and related compounds; ethanol, benzyl alcohol, methanol; propylene glycol, glycerol, phytol; inositol, furfuryl alcohol, menthol; aldehydes, ketones, quinones, derivatives and related compounds; acetaldehyde, butyraldehyde, benzaldehyde, acrolein, furfural, glyoxal; acetone and butanone; anthraquinone; a carbohydrate; monosaccharides, disaccharides, trisaccharides; alkaloids, amines and other bases; pyridine (including niacin, nicotinamide); pyrimidine (including cytosine, thymine); purine (including guanine, adenine, xanthine/hypoxanthine, kinetin); pyrrole; quinoline (including isoquinoline); morphinans, tropanes, cinchonines (cinchonans), nucleotides, oligonucleotides, derivatives and related compounds; guanosine, cytosine, adenosine, thymidine, inosine; amino acids, oligopeptides, derivatives and related compounds; an ester; phenols and related compounds; heterocyclic compounds and derivatives; pyrrole, tetrapyrrole; flavonoids; an indole; lipids (including fatty acids and triglycerides), derivatives and related compounds; carotenoids, phytoene and sterols, isoprenoids, including terpenes; and any modified form of the above molecules. In some embodiments, the metabolite is a product of the metabolism of the endogenous substance. In some embodiments, the metabolite is a product of the metabolism of the exogenous material. In some embodiments, the metabolite is a product of the metabolism of the endogenous and exogenous substances.
Some metabolites are indicated by CAS numbers. Some metabolites are represented by ID numbers of HMDB (human metabolomics database, human Metabolome Database).
As described above, the "CAS number" refers to a CAS number assigned to each substance by the American society for chemical abstracts of lower hierarchy (Chemical Abstracts Service, CAS for short). In the biochemical field, CAS numbers are a representation of unique identification codes for substances, i.e., each CAS number corresponds to a unique substance. Similarly, the ID number of HMDB refers to a unique ID number corresponding to each substance in the human metabonomics database (Human Metabolome Database).
As used herein, the term "complications" refers to the occurrence of one disease in the course of its development that causes another disease or condition in the same patient, the latter being the former complication.
As used herein, the term "cardiovascular event" refers to the first occurrence of fatal or non-fatal myocardial infarction, fatal or non-fatal stroke, hospitalization for heart failure, or sudden death. Cardiovascular events generally refer to serious consequences of cardiovascular disease, including sudden death, acute myocardial infarction, acute heart failure, acute cerebral infarction, etc., which are the leading causes of disability or death in patients. Acute myocardial infarction refers to an acute condition in which the coronary arteries are blocked, the heart muscle is necrotized due to lack of blood supply, and the heart function is damaged, possibly endangering life. Acute heart failure refers to a clinical syndrome that acute heart congestion, pulmonary edema and tissue and organ hypoperfusion and cardiogenic shock occur due to acute attack or aggravated left heart dysfunction, such as heart contractility decrease, acute heart discharge sudden drop, pulmonary circulation pressure increase and peripheral circulation resistance increase, and pulmonary circulation congestion is caused, and is most common in left heart failure. Acute heart failure can be aggravated acutely or suddenly on the basis of original chronic heart failure, and the acute heart failure is often life-threatening and needs urgent rescue. Acute cerebral infarction refers to brain tissue necrosis caused by sudden interruption of cerebral blood supply, and is mainly caused by atherosclerosis and thrombosis of arteries supplying cerebral blood, and causes stenosis and even occlusion of a lumen, resulting in occurrence of focal acute cerebral ischemia.
As used herein, the term "change in level" refers to a value that is changed relative to a control level or normal level. The normal level is a history-based normal control sample or a normal control sample tested in the same experiment. The specific "normal" value will depend, for example, on the type of assay (e.g., ELISA, enzymatic activity, immunohistochemistry, PCR, spectroscopy), the sample to be tested (e.g., cell type and culture conditions, sample to be tested), and other considerations known to those skilled in the art. The control sample may be used to define a threshold between normal and abnormal.
As used herein, the term "control level" refers to the level of a biomarker in a sample from a subject or group of subjects known to have a particular condition or not.
As used herein, the term "control sample" refers to any clinically relevant control sample, including, for example, a sample from a healthy subject not suffering from a cardiovascular disease, or from an earlier point in time, for example, prior to treatment, or from a subject at an early stage of treatment or disease. The control sample may be a purified sample, e.g., protein, nucleic acid, and/or lipid extracted with a kit. Such control samples may be diluted, e.g., serially diluted, to allow for quantitative determination of the analyte in the test sample. The control sample may comprise samples from one or more subjects. The control sample may also be a sample from an animal model, or from a tissue or cell line obtained from an animal model of cardiovascular disease, the activity or expression level of a biomarker in a control sample consisting of a set of measurements may be determined, for example, from any suitable statistical measure, such as, for example, a measure of concentration trend (including average, median or modal value), before onset, at an earlier point in time, at an earlier stage of the disease, or before administration of a treatment or a portion of a treatment for cardiomyopathy or other disorder, particularly with an agent known to induce cardiomyopathy (e.g., type 2 diabetes drug, chemotherapeutic agent treatment).
In one embodiment, the control is a standardized control, e.g., a control predetermined using an average of the expression levels of one or more markers from a population without cardiovascular disease. In yet another embodiment of the invention, the control level of the marker is the level of the marker in a normal sample from the subject.
As used herein, the term "biological sample" is a body fluid or tissue in which a marker of interest may be present. In certain embodiments, the sample is blood, vomit, saliva, lymph, cyst fluid, urine, fluid collected by bronchoalveolar lavage, fluid collected by peritoneal rinsing, or gynecological fluid. In one embodiment, the subject sample is a blood sample or a component thereof (e.g., serum). The sample may be a tissue sample from a subject, such as a heart tissue sample from a subject. In certain embodiments, the tissue is selected from the group consisting of bone, connective tissue, cartilage, lung, liver, kidney, muscle tissue, heart, pancreas, and skin. The cell sample or samples from laboratory animals may be used in many of the same experimental methods provided herein for use in human biological or subject samples.
Advantageous effects of the invention
Compared with the prior art, the biomarker can be used as a marker for characterizing hyperglycemia-related CVD. Prediction of whether a diabetic patient is at risk for cardiovascular disease, in particular cardiovascular events, is further enabled by these biomarkers. Thus, the biomarkers of the present application can be used to predict the risk of cardiovascular disease, particularly cardiovascular events (e.g., acute myocardial infarction, acute heart failure, acute cerebral infarction, and sudden death) in a subject (e.g., a subject with diabetes). The biomarker can be effectively used as a marker for predicting the cardiovascular disease risk of a diabetic patient, and has the advantages of noninvasive property, accuracy, early stage and high accuracy.
Embodiments of the present invention will be described in detail below with reference to the accompanying drawings and examples, but it will be understood by those skilled in the art that the following drawings and examples are only for illustrating the present invention and are not to be construed as limiting the scope of the present invention. Various objects and advantageous aspects of the present invention will become apparent to those skilled in the art from the following detailed description of the preferred embodiments and the accompanying drawings.
Drawings
FIG. 1 shows the results of analysis of principal components of plasma metabolites of different populations, wherein "NDM (non-CVD)" represents a diabetic and CVD-free sample; "NDM (with CVD)" means a sample of diabetes combined with CVD; "NGT (non CVD)" means a normoglycemic and CVD-free sample; "NGT (with CVD)" means a sample of euglycemic pooled CVD. CVD refers to the occurrence of cardiovascular events such as: myocardial infarction, cerebral infarction or admission due to heart failure.
FIG. 2 shows the results of OPLS-DA analysis of plasma metabolic differences between the diabetic-associated CVD population and the normoglycemic CVD-free population in the positive ion detection mode.
FIG. 3 shows the results of OPLS-DA analysis of plasma metabolic difference products in a diabetic-combined CVD population and a normoglycemic CVD-free population in an anion detection mode.
FIG. 4 shows the results of OPLS-DA analysis of plasma metabolic differences between diabetic and normoglycemic CVD-free populations in positive ion detection mode.
FIG. 5 shows the results of OPLS-DA analysis of plasma metabolic difference products in a diabetic CVD-free population versus a normoglycemic CVD-free population in an anion detection mode.
FIG. 6 shows the results of OPLS-DA analysis of plasma metabolic differences between normoglycemic and CVD populations and normoglycemic and CVD-free populations in the positive ion detection mode.
FIG. 7 shows the results of OPLS-DA analysis of plasma metabolic difference products in a normoglycemic and CVD-free population and a normoglycemic and CVD-free population in the negative ion detection mode.
A in fig. 8 shows a graph comparing the relative amounts of the biomarker dihydroxyacetone phosphate (Dihydroxyacetone phosphate) in different groups, wherein "NGT-CVD" in the abscissa indicates a normoglycemic and CVD-free sample, "NDM-CVD" indicates a diabetic and CVD-free sample, and "ndm+cvd" indicates a diabetic and CVD-free sample; the ROC analysis results are shown in B in fig. 8.
A in fig. 9 shows a graph comparing the relative amounts of the biomarker guanyltaurine (Taurocyamine) in different groups, wherein "NGT-CVD" in the abscissa indicates a normoglycemic and CVD-free sample, "NDM-CVD" indicates a diabetic and CVD-free sample, and "ndm+cvd" indicates a diabetic and CVD-free sample; b in fig. 9 shows ROC analysis results.
FIG. 10A shows a comparison of the relative amounts of the biomarker Lactosylceramide (d18:1/12:0) (Lactosylceramide (d18:1/12:0)) in different groups, wherein "NGT-CVD" in the abscissa indicates normoglycemic and CVD-free samples, "NDM-CVD" indicates diabetic and CVD-free samples, and "NDM+CVD" indicates diabetic and CVD-free samples; the ROC analysis results are shown in B in fig. 10.
FIG. 11A shows a graph comparing the relative amounts of the biomarker glycerophosphorylcholine (18:1/18:1) (Glycerophosphocholines PC (18:1/18:1)) in different groups, wherein "NGT-CVD" in the abscissa indicates normoglycemic and CVD-free samples, "NDM-CVD" indicates diabetic and CVD-free samples, "NDM+CVD" indicates diabetic and CVD-free samples; the ROC analysis results are shown in B in fig. 11.
A in fig. 12 shows a graph comparing the relative amounts of the biomarker palmitoyl sphingomyelin Palmitoyl sphingomyelin in different groups, wherein "NGT-CVD" in the abscissa represents a normoglycemic and CVD-free sample, "NDM-CVD" represents a diabetic and CVD-free sample, and "ndm+cvd" represents a diabetic and CVD-free sample; the ROC analysis results are shown in B in fig. 12.
FIG. 13A shows a graph comparing the relative amounts of the biomarker glycerophosphorylcholine (20:0/18:2) (Glycerophosphocholines PC (20:0/18:2)) in different groups, wherein "NGT-CVD" in the abscissa indicates normoglycemic and CVD-free samples, "NDM-CVD" indicates diabetic and CVD-free samples, "NDM+CVD" indicates diabetic and CVD-free samples; the ROC analysis results are shown in B in fig. 13.
FIG. 14A shows a graph comparing the relative amounts of the biomarker diglycerides (22:1n9/0:0/22:6n3) (Diacylglycerol DAG (22:1n9/0:0/22:6n3)) in different groups, wherein "NGT-CVD" in the abscissa indicates normoglycemic and CVD-free samples, "NDM-CVD" indicates diabetic and CVD-free samples, "NDM+CVD" indicates diabetic and CVD-free samples; the ROC analysis results are shown in B in fig. 14.
FIG. 15A shows a graph comparing the relative amounts of the biomarker glycerophosphorylcholine (24:1/14:0) (Glycerophosphocholines PC (24:1/14:0)) in different groups, wherein "NGT-CVD" in the abscissa indicates normoglycemic and CVD-free samples, "NDM-CVD" indicates diabetic and CVD-free samples, "NDM+CVD" indicates diabetic and CVD-free samples; the ROC analysis results are shown in B in fig. 15.
FIG. 16A shows a comparison of the relative amounts of the biomarker Glucosylceramide (d18:1/18:0) (glucopyranosyl ceramide (d18:1/18:0)) in different groups, wherein "NGT-CVD" in the abscissa indicates normoglycemic and CVD-free samples, "NDM-CVD" indicates diabetic and CVD-free samples, "NDM+CVD" indicates diabetic and CVD-free samples; the ROC analysis results are shown in B in fig. 16.
A in fig. 17 shows a comparison of the relative amounts of the biomarker diglycerides (18:4/24:1/0:0) (Diacylglycerol DAG (18:4/24:1/0:0)) in different groups, wherein "NGT-CVD" in the abscissa indicates a normoglycemic and CVD-free sample, "NDM-CVD" indicates a diabetic and CVD-free sample, and "ndm+cvd" indicates a diabetic and CVD-free sample. B in fig. 17 shows ROC analysis results.
FIG. 18A shows a graph comparing the relative amounts of the biomarker sphingomyelin (d18:1/24:1) (sphingomyelins SM (d18:1/24:1)) in different groups, wherein "NGT-CVD" in the abscissa indicates normoglycemic and CVD-free samples, "NDM-CVD" indicates diabetic and CVD-free samples, and "NDM+CVD" indicates diabetic and CVD-free samples; the ROC analysis results are shown in B in fig. 18.
FIG. 19A shows a graph comparing the relative amounts of the biomarker 1-stearoyl phosphatidylinositol (1-stearoyl phosphatidylinositol) in different groups, wherein "NGT-CVD" in the abscissa indicates a normoglycemic and CVD-free sample, "NDM-CVD" indicates a diabetic and CVD-free sample, and "NDM+CVD" indicates a diabetic and CVD-free sample; the ROC analysis results are shown in B in fig. 19.
A in fig. 20 shows a graph comparing the relative amounts of the biomarker stearoyl carnitine (stearoyl carnitine) in different groups, wherein "NGT-CVD" in the abscissa indicates a normoglycemic and CVD-free sample, "NDM-CVD" indicates a diabetic and CVD-free sample, and "ndm+cvd" indicates a diabetic and CVD-free sample. The ROC analysis results are shown in B in fig. 20.
Fig. 21 shows ROC analysis results of the biomarker palmitoyl sphingomyelin Palmitoyl sphingomyelin in different samples.
Detailed Description
The invention will now be described with reference to the following examples, which are intended to illustrate the invention, but not to limit it.
The experiments and methods described in the examples were performed substantially in accordance with conventional methods well known in the art and described in various references unless specifically indicated. For example, for the conventional techniques of immunology, biochemistry, chemistry, molecular biology, microbiology, cell biology, genomics and recombinant DNA used in the present invention, reference may be made to Sambrook (Sambrook), friech (Fritsch) and manitis (Maniatis), molecular cloning: laboratory Manual (MOLECULAR CLONING: A LABORATORY MANUAL), edit 2 (1989); the handbook of contemporary molecular biology (CURRENT PROTOCOLS IN MOLECULAR BIOLOGY) (edited by f.m. ausubel (f.m. ausubel) et al, (1987)); series (academic publishing company) of methods in enzymology (METHODS IN ENZYMOLOGY): PCR2: practical methods (PCR 2: A PRACTICAL APPROACH) (M.J. MaxPherson (M.J. MacPherson), B.D. Thoms (B.D. Hames) and G.R. Taylor (G.R. Taylor) editions (1995)), and animal cell CULTURE (ANIMAL CELL CULTURE) (R.I. French Lei Xieni (R.I. Freshney) editions (1987)).
In addition, the specific conditions are not specified in the examples, and the process is carried out according to conventional conditions or conditions recommended by the manufacturer. The reagents or apparatus used were conventional products commercially available without the manufacturer's attention. Those skilled in the art will appreciate that the examples describe the invention by way of example and are not intended to limit the scope of the invention as claimed. All publications and other references mentioned herein are incorporated by reference in their entirety.
Example 1 Experimental sample and article
Experimental samples: 240, 4 groups of clinical patient plasma samples (fasting plasma) were selected, including: a normoglycemic CVD-free sample (NGT non CVD), a normoglycemic CVD-free sample (NGT with CVD), a diabetic CVD-free sample (NDM non CVD), a diabetic CVD-combined sample (NDM with CVD).
Experimental reagent and consumable: chromatographic grade methanol, acetonitrile solvent (merck company), chromatographic grade formic acid (sammer technology) 1.5ml, 2.0ml EP tube.
Instrument apparatus: ultra performance liquid chromatograph (Waters acquisition) TM UPLC system), high resolution time of flight mass spectrometer Waters SYNAPT G2 HDMS (Waters Corp., manchester, UK), cryogenic refrigerated centrifuge (Sieimer flied), micropipette (Ai Bende), ultra low temperature refrigerator (Sieimer flied).
EXAMPLE 2 extraction and analysis of metabolites
1. Experimental method
1. Sample solution preparation
Before the experiment, the sample was taken out of the-80 ℃ ultra-low temperature refrigerator and thawed at room temperature. mu.L of methanol-acetonitrile (v/v=4:1) was added to 200. Mu.L of plasma sample, centrifuged at 4 ℃,12,000g for 30min, and the supernatant was taken and analyzed by a liquid chromatography-mass spectrometer.
2. Detection condition of liquid chromatography-mass spectrometer
Ultra-high performance liquid chromatography detection conditions: the instrument was Waters AcquityTM Ultra Performance LC System (Waters Corporation, milford, MA, USA); chromatographic column: waters Acquity BEH C18 column (100 mm. Times.2.1 mm,1.7 μm); mobile phase: phase A: 0.1% aqueous formic acid+2 mM ammonium formate; and B phase: 0.1% acetonitrile formate solution+2 mM ammonium formate; elution gradient flow: 0-2 minutes, 1.0% to 45% b;2-10 minutes, 45% to 70% b;10-13 minutes, 70% b to 99%;13-22 minutes, 99% B;22-24 minutes, 1.0% B elution balance; the flow rate is 0.45mL/min; the sample chamber temperature was 4 ℃.
High resolution time-of-flight mass spectrometer detection conditions: the instrument used was a Waters synpt G2HDMS (Waters corp., manchester, UK); the ion source is an electrospray ion source; detection mode: positive and negative ion detection modes; capillary voltage: 3.0kV (positive ion detection mode), 2.5kV (negative ion detection mode); taper hole voltage: 40V; extraction cone voltage: 4V; desolventizing gas flow rate: 800L/h; desolventizing gas temperature: 450 ℃; taper hole gas flow rate: the ion source temperature is 100 ℃ at 30L/h; the scanning time interval is 0.1s; delay time: 0.02s; correction fluid: leucine enkephalin; data collection quality range: m/z is 100-1200Da.
3. Data multivariate statistical analysis
Metabonomics raw data preprocessing
And automatically completing preprocessing such as spectrum peak identification, noise filtering and the like on UPLC-Q-TOF/MS original data by using marker Lynx (MassLynx SCN 633) software in MassLynx V4.1. The parameters of the processing method are set as follows: retention time range: 0.5-15min; the mass range is as follows: 50-1200amu; and (3) a quality window: 0.02Da, peak intensity threshold (count): 300, retention time window: 0.2s, and the noise level is eliminated by 6. A three-dimensional matrix is obtained that includes retention time, exact mass-to-charge ratio, and ion peak intensity/area composition.
Metabonomics data multivariate statistical analysis
The data matrix obtained after the pretreatment is imported into SIMCA-P software (Umetrics AB, sweden,13.0.3 version) for multi-element statistical analysis, and the data is subjected to average automation and Pareto scale pretreatment, and Principal Component Analysis (PCA) and orthogonal partial least squares-discriminant analysis (OPLS-DA) are sequentially carried out.
(1) Principal Component Analysis (PCA)
The data is subjected to pattern recognition by using an unsupervised Principal Component Analysis (PCA), which can reflect the original state of the data, and is used for examining the separation condition of each group of data profiles and evaluating the interpretation ability R2X and the prediction ability Q2 of the established model. However, PCA is not conducive to accurate determination of inter-group differences because it cannot ignore intra-group errors and random errors that are not relevant for the purpose of the study.
(2) Orthogonal partial least squares-discriminant analysis (OPLS-DA)
Based on PCA analysis, the data were further analyzed by an orthogonal partial least squares-discriminant analysis (OPLS-DA) method, and the interpretation ability R2X and the prediction ability Q2 of the model were evaluated. The analysis results are represented by Score plot (Score plot), S-plot, variable projection importance (VIP) plot, and Loading plot (Loading plot). The grouping information of each group of data can be observed through the score graph; s-plot reflects the influence of each variable on sample grouping, each point scattered at two ends of an S curve in the graph represents a variable, and the farther from the origin, namely, the greater the degree of dispersion, the greater the contribution of the point to the grouping; the VIP value reflects the contribution of each variable to the sample grouping, with a greater VIP value indicating a stronger contribution of the variable to the grouping; the farther a variable is from the center in the load map (Loading plot), the greater its contribution to the packet. And (3) through the loading analysis and the VIP analysis of the S-plot, finding out the variables which have important contributions to the difference among the distinguishing groups from the established OPLS-DA model.
2. Experimental results
1. Plasma metabolic profile analysis of diabetic population
Plasma metabonomics analysis was performed on plasma samples from normoglycemic non-CVD (NGT non-CVD), normoglycemic co-CVD (NGT with CVD), diabetic non-CVD (NDM non-CVD) and diabetic co-CVD (NDM with CVD) 4 groups of people using an optimized UPLC-Q-TOF/MS metabonomics analysis method. The results of principal component analysis (PCA, FIG. 1) show that (1) the plasma metabolic profile of the 4 groups of people is distributed in three quadrants, and the plasma metabolic profile of the normoglycemic people is relatively concentrated and separated without being affected by the combination of CVD; (2) The plasma metabolism profile of the diabetic patient is obviously separated from that of the normoglycemic person, and the plasma metabolism profile of the patient with or without CVD is also obviously separated due to the influence of CVD, which indicates that whether the CVD has obvious influence on the plasma metabolism of the diabetic patient in the diabetic population.
2. Screening of specific markers
(1) Inter-group differential metabolites associated with diabetes combined CVD
The collected plasma metabolic profile data of normoglycemic and CVD-free populations and diabetic co-CVD populations were subjected to OPLS-DA analysis using multivariate statistical analysis (fig. 2, fig. 3). Screening standard by S-Plot inter-group variance variable: VIP >1, p 1P >0, p (corr) > + -0.6 screening threshold, 304 inter-group difference variables were obtained in positive ion mode, and 119 inter-group difference variables were obtained in negative ion mode.
(2) Inter-group differential metabolites associated with diabetes
The collected plasma metabolic profile data of normoglycemic and CVD-free populations and diabetic CVD-free populations were subjected to OPLS-DA analysis using multivariate statistical analysis (fig. 4, fig. 5). Screening standard by S-Plot inter-group variance variable: VIP >1, p 1P >0, p (corr) > + -0.6 are screening thresholds, 786 inter-group difference variables are obtained in positive ion mode, and 164 inter-group difference variables are obtained in negative ion mode.
(3) CVD-related group differential metabolites
The collected plasma metabolic profile data of normoglycemic and CVD-free populations and normoglycemic combined CVD populations were subjected to OPLS-DA analysis using multivariate statistical analysis (fig. 6, fig. 7). Screening standard by S-Plot inter-group variance variable: VIP >1, p 1P >0, p (corr) > + -0.6 are screening thresholds, 54 inter-group difference variables are obtained in positive ion mode, and 86 inter-group difference variables are obtained in negative ion mode.
(4) Specific markers for diabetes-related CVD
Comparing plasma metabonomics data of the diabetic co-CVD population, the diabetic non-CVD population, and the normoglycemic co-CVD population with the normoglycemic non-CVD population, respectively, to obtain 3 groups of inter-group differential metabolites, which are respectively an inter-group differential metabolite (a) associated with hyperglycemia with CVD, a metabolite (B) associated with diabetes, and a metabolite (C) associated with CVD alone. And finally obtaining 72 specific biomarkers of diabetes-related CVD after eliminating the influence of simple diabetes factors and CVD factors on organisms by a deduction method (60 biomarkers are obtained from positive ion detection modes by screening, 13 negative ion detection modes are obtained, and 1 metabolite is detected in both detection modes). The VIP value is larger than 1, the relative peak area is larger than 1000, the change multiple is larger than 5, and 13 metabolites (table 1) are finally obtained, can be used as plasma biomarkers for representing the CVD caused by hyperglycemia, and have the potential of assisting clinical diagnosis and the function of clinical CVD risk early warning.
TABLE 1 list of biomarkers specifically related to diabetes-induced CVD
EXAMPLE 3 biomarker Dihydroxyacetone phosphate Dihydroxyacetone
phosphate is used for blood of different people
Detection of relative content in pulp
This example takes the biomarker dihydroxyacetone phosphate Dihydroxyacetone phosphate as an example, and detects whether it can be used as a biomarker for predicting the risk of cardiovascular diseases in diabetic subjects. Other biomarkers or combinations as described above may be used in accordance with the methods described in this example to predict cardiovascular disease risk in a diabetic subject.
Experimental samples: group 3 clinical patient plasma samples (fasting plasma) comprising: 60 normal blood glucose non-CVD samples (NGT non-CVD), 60 diabetes non-CVD samples (NDM non-CVD), 60 diabetes combined CVD samples (NDM with CVD).
Experimental reagent and consumable: chromatographic grade methanol, acetonitrile solvent (merck company), chromatographic grade formic acid (sammer technology) 1.5ml, 2.0ml EP tube.
Instrument apparatus: ultra performance liquid chromatograph (Waters acquisition) TM UPLC system, high resolution time-of-flight mass spectrometer Watters synpt G2 HDMS (Waters corp., manchester, UK), cryo-centrifuge (sameifei), micropipette (Ai Bende), ultra-low temperature refrigerator (sameifei).
The experimental method comprises the following steps:
1. The extraction of metabolites was performed as described in example 2. The LC-MS detection conditions were as described in example 2.
Experimental results:
based on established examination methods, the relative amounts of the biomarker dihydroxyacetone phosphate Dihydroxyacetone phosphate in samples with diabetes and CVD (NDM with CVD) and samples without diabetes and CVD (NDM non CVD) were examined and analyzed. As shown in a in fig. 8, by comparing peak areas of the biomarker in the two groups of samples, the results of the verification experiment show that the content of dihydroxyacetone phosphate Dihydroxyacetone phosphate in the samples with diabetes and CVD (NDM with CVD) is significantly higher than that in the samples without diabetes and CVD (NDM non CVD), and the change factor is about 587 times. The verification experiment result shows that the content of the biomarker dihydroxyacetone phosphate Dihydroxyacetone phosphate can distinguish whether a diabetic patient is accompanied with a CVD event, and the area under the curve is 0.6042 and 95% CI (0.4973,0.7111) through ROC curve analysis, so that the biomarker has higher prediction accuracy (B in figure 8) and can be used as a biomarker for judging the cardiovascular disease risk of a diabetic subject.
Example 4 relative content of biomarker Taurocyamine, guanyl taurate in plasma of different populations
Measuring
This example takes the biomarker Taurocyamine as an example, and detects whether it can be used as a biomarker for predicting the risk of cardiovascular disease in diabetic subjects. Other biomarkers or combinations as described above may be used in accordance with the methods described in this example to predict cardiovascular disease risk in a diabetic subject.
Experimental samples: group 3 clinical patient plasma samples (fasting plasma) comprising: 60 normal blood glucose non-CVD samples (NGT non-CVD), 60 diabetes non-CVD samples (NDM non-CVD), 60 diabetes combined CVD samples (NDM with CVD).
The experimental reagents and consumables and the instrument equipment are the same as in example 3.
The experimental method comprises the following steps: 1. metabolite extraction following the procedure described in example 2, the LC-MS detection conditions were as described in example 2.
Experimental results:
based on established examination methods, the relative content of the biomarker Taurocyamine in diabetic and CVD-bearing samples (NDM with CVD) and diabetic and CVD-free samples (NDM non CVD) was examined and analyzed. As shown in a in fig. 9, by comparing the peak areas of the biomarker in the two groups of samples, the results of the verification experiment find that the content of Taurocyamine amidine taurine in the samples with diabetes and CVD (NDM with CVD) is significantly lower than that in the samples without diabetes and CVD (NDM non CVD), and the change multiple is 5. The verification experiment result shows that the content of the biomarker guanyltaurine Taurocyamine can distinguish whether a diabetic patient is accompanied with a CVD event, and the area under the curve is 0.8708 and 95% CI (0.8045 0.9371) through ROC curve analysis, so that the biomarker guanyltaurine Taurocyamine has stronger prediction accuracy (B in fig. 9) and can be used as a biomarker for judging the risk of cardiovascular diseases of a diabetic subject.
Example 5 biomarker lactose ceramide (d18:1/12:0) (Lactosylceramide (d18:1/12:
0) Detection of the relative content in the plasma of different populations
This example exemplifies the biomarker Lactosylceramide (d18:1/12:0) (Lactosylceramide (d18:1/12:0)) which is used as a biomarker for predicting the risk of cardiovascular disease in diabetic subjects. Other biomarkers or combinations as described above may be used in accordance with the methods described in this example to predict cardiovascular disease risk in a diabetic subject.
Experimental samples: group 3 clinical patient plasma samples (fasting plasma) comprising: 60 normal blood glucose non-CVD samples (NGT non-CVD), 60 diabetes non-CVD samples (NDM non-CVD), 60 diabetes combined CVD samples (NDM with CVD).
The experimental reagents and consumables and the instrument equipment are the same as in example 3. The experimental method comprises the following steps: 1. metabolite extraction following the procedure described in example 2, the LC-MS detection conditions were as described in example 2.
Experimental results:
based on established examination methods, the relative amounts of the biomarker Lactosylceramide (d18:1/12:0) (Lactosylceramide (d18:1/12:0)) in samples with diabetes and with CVD (NDM with CVD) and in samples with diabetes and without CVD (NDM non CVD) were examined and analyzed. As shown in a in fig. 10, by comparing peak areas of the biomarker in the two groups of samples, the results of the verification experiment found that the content of Lactosylceramide (d18:1/12:0) (lactosylamide (d18:1/12:0)) in the samples with diabetes and CVD (NDM with CVD) was significantly higher than that in the samples with diabetes and CVD (NDM non CVD) by a factor of 41. The verification experiment result shows that the content of the biomarker lactose ceramide (d18:1/12:0) (Lactosylceramide (d18:1/12:0)) can be used for distinguishing whether a diabetic patient is accompanied with a CVD event, and the biomarker can be used as a biomarker for judging the risk of cardiovascular diseases of a diabetic subject through ROC curve analysis, wherein the area under the curve is 0.8574, 95% CI (0.7856,0.9291), and the biomarker has stronger prediction accuracy (B in FIG. 10).
EXAMPLE 6 biomarker glycerophosphochloride (18:1/18:1) (Glycerol phosphatidylcholine PC)
(18:1/18:1)) in the plasma of different populations
This example exemplifies the biomarker glycerophosphorylcholine (18:1/18:1) (Glycerophosphocholines PC (18:1/18:1)) which is used as a biomarker for predicting the risk of cardiovascular disease in diabetic subjects. Other biomarkers or combinations as described above may be used in accordance with the methods described in this example to predict cardiovascular disease risk in a diabetic subject.
Experimental samples: group 3 clinical patient plasma samples (fasting plasma) comprising: 60 normal blood glucose non-CVD samples (NGT non-CVD), 60 diabetes non-CVD samples (NDM non-CVD), 60 diabetes combined CVD samples (NDM with CVD).
The experimental reagents and consumables and the instrument equipment are the same as in example 3. The experimental method comprises the following steps: 1. metabolite extraction following the procedure described in example 2, and LC-MS detection conditions following the procedure described in example 2
Experimental results:
based on established examination methods, the relative amounts of the biomarker glycerophosphorylcholine (18:1/18:1) (Glycerophosphocholines PC (18:1/18:1)) in samples with diabetes and CVD (NDM with CVD) and samples with diabetes and no CVD (NDM non CVD) were examined and analyzed. As shown in a in fig. 11, by comparing peak areas of the biomarker in the two groups of samples, the results of the validation experiments found that the content of glycerophosphorylcholine (18:1/18:1) (Glycerophosphocholines PC (18:1/18:1)) in the samples with diabetes and CVD (NDM with CVD) was significantly higher than that in the samples without diabetes and CVD (NDM non CVD), by a factor > 10000. The verification experiment result shows that the content of the biomarker glycerophosphorylcholine (18:1/18:1) (Glycerophosphocholines PC (18:1/18:1)) can be used for distinguishing whether a diabetic patient is accompanied with a CVD event, and the area under the curve is 0.6944 and 95% CI (0.5968,0.7921) through ROC curve analysis, so that the biomarker has better prediction accuracy (B in FIG. 11) and can be used as a biomarker for judging the cardiovascular disease risk of a diabetic subject.
Example 7 biomarker palmitoyl sphingomyelin palmitoyl sphingomylin in plasma of different people
Relative content detection of (2)
This example takes the biomarker palmitoyl sphingomyelin Palmitoyl sphingomyelin as an example to examine whether it can be used as a biomarker for predicting the risk of cardiovascular disease in diabetic subjects. Other biomarkers or combinations as described above may be used in accordance with the methods described in this example to predict cardiovascular disease risk in a diabetic subject.
Experimental samples: group 3 clinical patient plasma samples (fasting plasma) comprising: 60 normal blood glucose non-CVD samples (NGT non-CVD), 60 diabetes non-CVD samples (NDM non-CVD), 60 diabetes combined CVD samples (NDM with CVD).
The experimental reagents and consumables and the instrument equipment are the same as in example 3. The experimental method comprises the following steps: 1. metabolite extraction following the procedure described in example 2, the LC-MS detection conditions were as described in example 2. Experimental results:
based on established examination methods, the relative amounts of the biomarker palmitoyl sphingomyelin Palmitoyl sphingomyelin in diabetic and CVD-bearing samples (NDM with CVD) and diabetic and CVD-free samples (NDM non CVD) were examined and analyzed. As shown in a in fig. 12, by comparing peak areas of the biomarker in the two groups of samples, the results of the verification experiment found that the content of palmitoyl sphingomyelin Palmitoyl sphingomyelin in the samples with diabetes and CVD (NDM with CVD) was significantly higher than that in the samples without diabetes and CVD (NDM non CVD), by a factor of 34. The verification experiment result shows that the content of the biomarker palmitoyl sphingomyelin Palmitoyl sphingomyelin can distinguish whether a diabetic patient is accompanied with a CVD event, and the area under the curve is 0.9167 and 95% CI (0.8586,0.9747) through ROC curve analysis, so that the biomarker has stronger prediction accuracy (B in fig. 12) and can be used as a biomarker for judging the cardiovascular disease risk of the diabetic subject.
EXAMPLE 8 biomarker glycerophosphochloride (20:0/18:2) (Glycerol phosphatidylcholine PC
(20:0/18:2)) in the plasma of different populations
This example exemplifies the biomarker glycerophosphorylcholine (20:0/18:2) (Glycerophosphocholines PC (20:0/18:2)) which is used as a biomarker for predicting the risk of cardiovascular disease in diabetic subjects. Other biomarkers or combinations as described above may be used in accordance with the methods described in this example to predict cardiovascular disease risk in a diabetic subject.
Experimental samples: group 3 clinical patient plasma samples (fasting plasma) comprising: 60 normal blood glucose non-CVD samples (NGT non-CVD), 60 diabetes non-CVD samples (NDM non-CVD), 60 diabetes combined CVD samples (NDM with CVD).
The experimental reagents and consumables and the instrument equipment are the same as in example 3. The experimental method comprises the following steps: 1. metabolite extraction following the procedure described in example 2, the LC-MS detection conditions were as described in example 2. Experimental results:
based on established examination methods, the relative amounts of the biomarker glycerophosphorylcholine (20:0/18:2) (Glycerophosphocholines PC (20:0/18:2)) in samples with diabetes and CVD (NDM with CVD) and samples with diabetes and no CVD (NDM non CVD) were examined and analyzed. As shown in a in fig. 13, by comparing peak areas of the biomarker in the two groups of samples, the results of the validation experiment found that the content of glycerophosphorylcholine (20:0/18:2) (Glycerophosphocholines PC (20:0/18:2)) in the samples with diabetes and CVD (NDM with CVD) was significantly higher than that in the samples with diabetes and CVD (NDM non CVD), with a fold change of 35 times. The verification experiment result shows that the content of the biomarker glycerophosphorylcholine (20:0/18:2) (Glycerophosphocholines PC (20:0/18:2)) can be used for distinguishing whether a diabetic patient is accompanied with a CVD event, and the area under the curve is 0.7589 and 95% CI (0.6619,0.8559) through ROC curve analysis, so that the biomarker has high prediction accuracy (B in FIG. 13) and can be used as a biomarker for judging the cardiovascular disease risk of a diabetic subject.
EXAMPLE 9 biomarker diglyceride (22:1n9/0:0/22:6n3) (diacetylglycol)
DAG(22:
1n 9/0:0/22:6n3)) in the plasma of different people
This example exemplifies the biomarker diglyceride (22:1n9/0:0/22:6n3) (Diacylglycerol DAG (22:1n9/0:0/22:6n3)) that could be used as a biomarker for predicting the risk of cardiovascular disease in diabetic subjects. Other biomarkers or combinations as described above may be used in accordance with the methods described in this example to predict cardiovascular disease risk in a diabetic subject.
Experimental samples: group 3 clinical patient plasma samples (fasting plasma) comprising: 60 normal blood glucose non-CVD samples (NGT non-CVD), 60 diabetes non-CVD samples (NDM non-CVD), 60 diabetes combined CVD samples (NDM with CVD).
The experimental reagents and consumables and the instrument equipment are the same as in example 3. The experimental method comprises the following steps: 1. metabolite extraction following the procedure described in example 2, the LC-MS detection conditions were as described in example 2. Experimental results:
based on established examination methods, the relative amounts of the biomarkers diglyceride (22:1n9/0:0/22:6n3) (Diacylglycerol DAG (22:1n9/0:0/22:6n3)) in samples with diabetes and with CVD (NDM with CVD) and samples without diabetes and CVD (NDM non CVD) were examined and analyzed. As shown in a in fig. 14, by comparing peak areas of the biomarker in the two groups of samples, the results of the validation experiments found that the content of diglyceride (22:1n9/0:0/22:6n3) (Diacylglycerol DAG (22:1n9/0:0/22:6n3)) was significantly higher in the samples with diabetes and CVD (NDM with CVD) than in the samples without diabetes and CVD (NDM non CVD), by a factor of 1074. The verification experiment result shows that the content of the biomarker diglyceride (22:1n9/0:0/22:6n3) (Diacylglycerol DAG (22:1n9/0:0/22:6n3)) can be used for distinguishing whether a diabetic patient is accompanied with a CVD event, and the area under the curve is 0.8158, 95% CI (0.7354,0.8963) through ROC curve analysis, so that the biomarker has stronger prediction accuracy (B in fig. 14) and can be used as a biomarker for judging the risk of cardiovascular diseases of a diabetic subject.
EXAMPLE 10 biomarker glycerophosphochloride (24:1/14:0) (Glycerol phosphatidylcholine PC)
(24:1/14:0)) in the plasma of different populations
This example exemplifies the biomarker glycerophosphorylcholine (24:1/14:0) (Glycerophosphocholines PC (24:1/14:0)) which is used as a biomarker for predicting the risk of cardiovascular disease in diabetic subjects. Other biomarkers or combinations as described above may be used in accordance with the methods described in this example to predict cardiovascular disease risk in a diabetic subject.
Experimental samples: group 3 clinical patient plasma samples (fasting plasma) comprising: 60 normal blood glucose non-CVD samples (NGT non-CVD), 60 diabetes non-CVD samples (NDM non-CVD), 60 diabetes combined CVD samples (NDM with CVD).
The experimental reagents and consumables and the instrument equipment are the same as in example 3. The experimental method comprises the following steps: 1. metabolite extraction following the procedure described in example 2, the LC-MS detection conditions were as described in example 2. Experimental results:
based on established examination methods, the relative amounts of the biomarker glycerophosphorylcholine (24:1/14:0) (Glycerophosphocholines PC (24:1/14:0)) in samples with diabetes and CVD (NDM with CVD) and samples with diabetes and no CVD (NDM non CVD) were examined and analyzed. As shown in a in fig. 15, by comparing peak areas of the biomarker in the two groups of samples, the results of the validation experiment found that the content of glycerophosphorylcholine (24:1/14:0) (Glycerophosphocholines PC (24:1/14:0)) in the samples with diabetes and CVD (NDM with CVD) was significantly higher than that in the samples without diabetes and CVD (NDM non CVD), with a fold change of 67 times. The verification experiment result shows that the content of the biomarker glycerophosphorylcholine (24:1/14:0) (Glycerophosphocholines PC (24:1/14:0)) can be used for distinguishing whether a diabetic patient is accompanied with a CVD event, and the area under the curve is 0.7810 and 95% CI (0.6937,0.8682) through ROC curve analysis, so that the biomarker has high prediction accuracy (B in FIG. 15) and can be used as a biomarker for judging the cardiovascular disease risk of a diabetic subject.
EXAMPLE 11 biomarker glucose ceramide (d18:1/18:0) (glucopyranosyl ceramide (d18:1
18:0)) in the plasma of different populations
This example takes the biomarker Glucosylceramide (d18:1/18:0) (glucopyranosyl ceramide (d18:1/18:0)) as an example, and detects whether it can be used as a biomarker for predicting the risk of cardiovascular disease in diabetic subjects. Other biomarkers or combinations as described above may be used in accordance with the methods described in this example to predict cardiovascular disease risk in a diabetic subject.
Experimental samples: group 3 clinical patient plasma samples (fasting plasma) comprising: 60 normal blood glucose non-CVD samples (NGT non-CVD), 60 diabetes non-CVD samples (NDM non-CVD), 60 diabetes combined CVD samples (NDM with CVD).
The experimental reagents and consumables and the instrument equipment are the same as in example 3. The experimental method comprises the following steps: 1. metabolite extraction following the procedure described in example 2, the LC-MS detection conditions were as described in example 2. Experimental results:
based on established examination methods, the relative content of the biomarker Glucosylceramide (d18:1/18:0) (glucopyranosyl ceramide (d18:1/18:0)) in samples with diabetes and with CVD (NDM with CVD) and in samples with diabetes and without CVD (NDM non CVD) was examined and analyzed. As shown in a in fig. 16, by comparing peak areas of the biomarker in the two groups of samples, the results of the verification experiment found that the content of Glucosylceramide (d18:1/18:0) (glucopyranosyl ceramide (d18:1/18:0)) in the samples with diabetes and CVD (NDM with CVD) was significantly higher than that in the samples with diabetes and CVD (NDM non CVD), by a factor of 1192. The verification experiment result shows that the content of the biomarker glucose ceramide (d18:1/18:0) (glucopyranosyl ceramide (d18:1/18:0)) can be used for distinguishing whether a diabetic patient is accompanied with a CVD event, and the area under the curve is 0.8019 and 95% CI (0.7189,0.8849) through ROC curve analysis, so that the biomarker glucose ceramide has stronger prediction accuracy (B in FIG. 16) and can be used as a biomarker for judging the risk of cardiovascular diseases of a diabetic subject.
EXAMPLE 12 biomarker diglyceride (18:4/24:1/0:0) (diacetylglycol)
DAG(18:4/
24:1/0:0)) in the plasma of different people
This example exemplifies the biomarker diglyceride (18:4/24:1/0:0) (Diacylglycerol DAG (18:4/24:1/0:0)) that could be used as a biomarker for predicting the risk of cardiovascular disease in diabetic subjects. Other biomarkers or combinations as described above may be used in accordance with the methods described in this example to predict cardiovascular disease risk in a diabetic subject.
Experimental samples: group 3 clinical patient plasma samples (fasting plasma) comprising: 60 normal blood glucose non-CVD samples (NGT non-CVD), 60 diabetes non-CVD samples (NDM non-CVD), 60 diabetes combined CVD samples (NDM with CVD).
The experimental reagents and consumables and the instrument equipment are the same as in example 3. The experimental method comprises the following steps: 1. metabolite extraction following the procedure described in example 2, and LC-MS detection conditions following the procedure described in example 2
Experimental results:
based on established examination methods, the relative amounts of the biomarkers diglyceride (18:4/24:1/0:0) (Diacylglycerol DAG (18:4/24:1/0:0)) in samples with diabetes and CVD (NDM with CVD) and samples without diabetes and CVD (NDM non CVD) were examined and analyzed. As shown in a in fig. 17, by comparing peak areas of the biomarker in the two groups of samples, the results of the validation experiments found that the content of diglyceride (18:4/24:1/0:0) (Diacylglycerol DAG (18:4/24:1/0:0)) in the samples with diabetes and CVD (NDM with CVD) was significantly higher than that in the samples with diabetes and CVD (NDM non CVD), the fold change was >10000 times. The verification experiment result shows that the content of the biomarker diglyceride (18:4/24:1/0:0) (Diacylglycerol DAG (18:4/24:1/0:0)) can distinguish whether a diabetic patient is accompanied with a CVD event, and the area under the curve is 0.7447 and 95% CI (0.6525,0.837) through ROC curve analysis, so that the biomarker has stronger prediction accuracy (B in FIG. 17) and can be used as a biomarker for judging the cardiovascular disease risk of a diabetic subject.
EXAMPLE 13 biomarker sphingomyelin (d18:1/24:1) (sphingamylins)
SM(d18:1/24:1))
Detection of relative amounts in plasma of different populations
This example takes the biomarker sphingomyelin (d18:1/24:1) (sphingomyelins SM (d18:1/24:1)) as an example, and detects whether it can be used as a biomarker for predicting the risk of cardiovascular disease in diabetic subjects. Other biomarkers or combinations as described above may be used in accordance with the methods described in this example to predict cardiovascular disease risk in a diabetic subject.
Experimental samples: group 3 clinical patient plasma samples (fasting plasma) comprising: 60 normal blood glucose non-CVD samples (NGT non-CVD), 60 diabetes non-CVD samples (NDM non-CVD), 60 diabetes combined CVD samples (NDM with CVD).
The experimental reagents and consumables and the instrument equipment are the same as in example 3. The experimental method comprises the following steps: 1. metabolite extraction following the procedure described in example 2, the LC-MS detection conditions were as described in example 2. Experimental results:
based on established examination methods, the relative amounts of the biomarker sphingomyelin (d18:1/24:1) (sphingomyelins SM (d18:1/24:1)) in samples with diabetes and CVD (NDM with CVD) and samples with diabetes and no CVD (NDM non CVD) were examined and analyzed. As shown in a in fig. 18, by comparing peak areas of the biomarker in the two groups of samples, the results of the validation experiment found that the content of sphingomyelin (d18:1/24:1) (sphingomyelins SM (d18:1/24:1)) in samples with diabetes and CVD (NDM with CVD) was significantly higher than that in samples with diabetes and no CVD (NDM non CVD), by a factor > 10000. The verification experiment result shows that the content of the biomarker sphingomyelin (d18:1/24:1) (sphingomyelins SM (d18:1/24:1)) can be used for distinguishing whether a diabetic patient is accompanied with a CVD event, and the area under the curve is 0.7519 and 95% CI (0.6606,0.8433) through ROC curve analysis, so that the biomarker has stronger prediction accuracy (B in fig. 18) and can be used as a biomarker for judging the cardiovascular disease risk of a diabetic subject.
EXAMPLE 14 biomarker 1-stearoyl phosphatidylinositol (1-
stearoyl glycosporinopool) relative levels in plasma of different populations
This example exemplifies the biomarker 1-stearoyl phosphatidylinositol (1-stearoyl phosphatidylinositol) which is tested for its ability to be a biomarker for predicting the risk of cardiovascular disease in diabetic subjects. Other biomarkers or combinations as described above may be used in accordance with the methods described in this example to predict cardiovascular disease risk in a diabetic subject.
Experimental samples: group 3 clinical patient plasma samples (fasting plasma) comprising: 60 normal blood glucose non-CVD samples (NGT non-CVD), 60 diabetes non-CVD samples (NDM non-CVD), 60 diabetes combined CVD samples (NDM with CVD).
The experimental reagents and consumables and the instrument equipment are the same as in example 3. The experimental method comprises the following steps: 1. metabolite extraction following the procedure described in example 2, the LC-MS detection conditions were as described in example 2.
Experimental results:
based on established examination methods, the relative amounts of the biomarker 1-stearoyl phosphatidylinositol (1-stearoyl phosphatidylinositol) in samples with diabetes and with CVD (NDM with CVD) and samples with diabetes and without CVD (NDM non CVD) were examined and analyzed. As shown in a in fig. 19, by comparing peak areas of the biomarker in the two groups of samples, the results of the verification experiments found that the content of 1-stearoyl phosphatidylinositol (1-stearoyl phosphatidylinositol) in the samples with diabetes and CVD (NDM with CVD) was significantly higher than that in the samples with diabetes and CVD (NDM non CVD) by a factor of 8. The verification experiment result shows that the content of the biomarker 1-stearoyl phosphatidylinositol (1-stearoyl phosphatidylinositol) can be used for distinguishing whether a diabetic patient is accompanied with a CVD event, and the area under the curve is 0.6830 and 95% CI (0.5775,0.7884) through ROC curve analysis, so that the biomarker has stronger prediction accuracy (B in FIG. 19) and can be used as a biomarker for judging the risk of cardiovascular diseases of a diabetic subject.
Example 15 phase of the biomarker stearoyl carnitine (Stearoylcannine) in plasma of different people
For content detection
This example takes the biomarker stearoyl carnitine (stearoyl carnitine) as an example, and detects whether it can be used as a biomarker for predicting the risk of cardiovascular disease in diabetic subjects. Other biomarkers or combinations as described above may be used in accordance with the methods described in this example to predict cardiovascular disease risk in a diabetic subject.
Experimental samples: group 3 clinical patient plasma samples (fasting plasma) comprising: 60 normal blood glucose non-CVD samples (NGT non-CVD), 60 diabetes non-CVD samples (NDM non-CVD), 60 diabetes combined CVD samples (NDM with CVD).
The experimental reagents and consumables and the instrument equipment are the same as in example 3. The experimental method comprises the following steps: 1. metabolite extraction following the procedure described in example 2, the LC-MS detection conditions were as described in example 2. Experimental results:
based on established examination methods, the relative content of the biomarker stearoyl carnitine (stearoyl carnitine) in samples with diabetes and CVD (NDM with CVD) and samples with diabetes and no CVD (NDM non CVD) was examined and analyzed. As shown in a in fig. 20, by comparing peak areas of the biomarker in the two groups of samples, the results of the verification experiment found that the content of stearoyl carnitine (steroyl carnitine) in the samples with diabetes and CVD (NDM with CVD) was significantly higher than that in the samples with diabetes and CVD (NDM non CVD) by a factor of 11. The verification experiment result shows that the content of the biomarker stearoyl carnitine (stearoyl carnitine) can be used for distinguishing whether a diabetic patient is accompanied with a CVD event, and the area under the curve is 0.7258 and 95% CI (0.6286,0.8230) through ROC curve analysis, so that the biomarker has stronger prediction accuracy (B in fig. 20) and can be used as a biomarker for judging the risk of cardiovascular diseases of a diabetic subject.
Example 16 biomarker palmitoyl sphingomyelin palmitoyl sphingomylin in plasma of different populations
Content detection of (2)
This example takes the biomarker palmitoyl sphingomyelin Palmitoyl sphingomyelin as an example to examine whether it can be used as a biomarker for predicting the risk of cardiovascular disease in diabetic subjects. Other biomarkers or combinations can be used in accordance with the methods described in this example to predict cardiovascular disease risk in a diabetic subject.
Experimental samples: 450 clinical patient plasma samples (fasting plasma) were selected, including 179 diabetic and CVD-bearing samples (NDM with CVD) and 271 diabetic and CVD-free samples (NDM non CVD).
The experimental reagents and consumables and the instrument equipment are the same as in example 3. The experimental method comprises the following steps: 1. metabolite extraction following the procedure described in example 2, the LC-MS detection conditions were as described in example 2.
2. Content determination
2.1 preparation of standard solution:
an appropriate amount of Palmitoyl sphingomyelin was precisely weighed and dissolved in methanol-acetonitrile (4:1) solvent to prepare a stock solution at a concentration of 200. Mu.g/mL.
2.2 establishment of standard curve
Stock solutions were diluted to standard solutions at levels of 2.5,5, 10, 20, 25, 40, 60 and 80. Mu.g/mL, respectively, and the control solution under item "2.1" was precisely aspirated and determined according to the LC-MS detection conditions in example 2. And drawing a standard curve by taking the concentration (mg/L) (X) of the reference substance as an abscissa and the peak area (Y) as an ordinate, and establishing a regression equation. y= 1817.2x-4743.6, r 2 = 0.9992, linear range 2.5-80 μg/mL, lowest limit of detection LOD1.0 μg/mL, lowest limit of quantification LOQ 2.5 μg/mL.
2.3 precision test
Precisely sucking 4 mu L of the control solution prepared under the item "2.1", continuously sampling for 6 times according to the LC-MS detection condition in the example 2, and calculating the relative standard deviation RSD% of the peak area to obtain the intra-day precision; the standard solution is continuously measured for three days (3 times per day of sample injection and 3 continuous days), and the relative standard deviation RSD of the peak area is calculated, namely the daytime precision.
2.4 repeatability test
1 sample was taken, 6 test solutions were prepared in parallel with the metabolite extraction and analysis method in example 2, and the content and relative standard deviation RSD% were calculated as determined by LC-MS detection conditions in example 2.
2.5 stability test
1 sample was taken, a sample solution was prepared according to the method for extracting and analyzing the metabolite in example 2, and samples were taken at 0,2,4,8, 12, 24 hours after the preparation, respectively, as determined according to the LC-MS detection conditions in example 2, and peak areas were measured, and the peak area relative standard deviation RSD% was calculated.
2.6 sample recovery test
9 parts of standard reference substance are precisely weighed, and the standard substance is added according to 80%,100% and 120% of 3 levels of known content, and the sample addition recovery rate and the relative standard deviation RSD% are calculated according to LC-MS detection conditions in the example 2.
3 content measurement results
The content of the biomarker Palmitoyl sphingomyelin in the samples with diabetes and CVD (NDM with CVD) and the samples without diabetes and CVD (NDM non CVD) was 22.1.+ -. 15.5. Mu.g/mL and 8.6.+ -. 4.6. Mu.g/mL, respectively, as determined by the content. The results of the validation experiments showed that the biomarker Palmitoyl sphingomyelin content can distinguish whether diabetic patients are accompanied by CVD events, and by ROC curve analysis, CVD was predicted at Palmitoyl sphingomyelin plasma concentration with an area under the curve of 0.8264, 95% ci (0.808,0.875). By analysis, the best value of sensitivity and specificity is determined as the best diagnostic threshold, palmitoyl sphingomyelin exceeds 11.19 mug/mL in the study population, the sensitivity and specificity of the predicted CVD risk are 79.7% and 69.3% respectively, and the predicted value is high (figure 21) and can be used as a biomarker for judging the risk of cardiovascular diseases of diabetic subjects.
Although specific embodiments of the invention have been described in detail, those skilled in the art will appreciate that: many modifications and variations of details may be made to adapt to a particular situation and the invention is intended to be within the scope of the invention. The full scope of the invention is given by the appended claims together with any equivalents thereof.
Claims (6)
1. Use of an agent for determining the level of a biomarker in a biological sample in the preparation of a kit for predicting whether a subject suffering from diabetes has: risk of cardiovascular disease; wherein the biomarker is a combination of palmitoyl sphingomyelin and sphingomyelin (d18:1/24:1); wherein the biological sample is selected from whole blood, plasma, or any combination thereof obtained from a subject.
2. The use of claim 1, wherein the subject is a human.
3. The use of claim 1, wherein the reagent determines the level of a biomarker in the biological sample by chromatography.
4. The use of claim 3, wherein the kit further comprises reagents and/or consumables for chromatography.
5. The use according to claim 3, wherein the chromatography is liquid chromatography.
6. The use of claim 4, wherein the reagent and/or consumable for chromatography is selected from a chromatographic column, an aqueous acetonitrile solution, ammonium acetate, ammonium formate, formic acid, or any combination thereof.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211510557.0A CN116087486B (en) | 2021-11-08 | 2021-11-08 | Biomarkers for early prediction of cardiovascular disease (CVD) in diabetics and uses thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211510557.0A CN116087486B (en) | 2021-11-08 | 2021-11-08 | Biomarkers for early prediction of cardiovascular disease (CVD) in diabetics and uses thereof |
CN202111315640.8A CN114113573B (en) | 2021-11-08 | 2021-11-08 | Biomarker for early prediction of cardiovascular disease (CVD) of diabetic patient and application thereof |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111315640.8A Division CN114113573B (en) | 2021-11-08 | 2021-11-08 | Biomarker for early prediction of cardiovascular disease (CVD) of diabetic patient and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116087486A CN116087486A (en) | 2023-05-09 |
CN116087486B true CN116087486B (en) | 2024-02-02 |
Family
ID=80381490
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211510543.9A Active CN116087485B (en) | 2021-11-08 | 2021-11-08 | Biomarkers for early prediction of cardiovascular disease (CVD) in diabetics and uses thereof |
CN202211510601.8A Pending CN116087487A (en) | 2021-11-08 | 2021-11-08 | Biomarkers for early prediction of cardiovascular disease (CVD) in diabetics and uses thereof |
CN202111315640.8A Active CN114113573B (en) | 2021-11-08 | 2021-11-08 | Biomarker for early prediction of cardiovascular disease (CVD) of diabetic patient and application thereof |
CN202211510557.0A Active CN116087486B (en) | 2021-11-08 | 2021-11-08 | Biomarkers for early prediction of cardiovascular disease (CVD) in diabetics and uses thereof |
CN202211513991.4A Pending CN116087489A (en) | 2021-11-08 | 2021-11-08 | Biomarkers for early prediction of cardiovascular disease (CVD) in diabetics and uses thereof |
CN202211510605.6A Pending CN116087488A (en) | 2021-11-08 | 2021-11-08 | Biomarkers for early prediction of cardiovascular disease (CVD) in diabetics and uses thereof |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211510543.9A Active CN116087485B (en) | 2021-11-08 | 2021-11-08 | Biomarkers for early prediction of cardiovascular disease (CVD) in diabetics and uses thereof |
CN202211510601.8A Pending CN116087487A (en) | 2021-11-08 | 2021-11-08 | Biomarkers for early prediction of cardiovascular disease (CVD) in diabetics and uses thereof |
CN202111315640.8A Active CN114113573B (en) | 2021-11-08 | 2021-11-08 | Biomarker for early prediction of cardiovascular disease (CVD) of diabetic patient and application thereof |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211513991.4A Pending CN116087489A (en) | 2021-11-08 | 2021-11-08 | Biomarkers for early prediction of cardiovascular disease (CVD) in diabetics and uses thereof |
CN202211510605.6A Pending CN116087488A (en) | 2021-11-08 | 2021-11-08 | Biomarkers for early prediction of cardiovascular disease (CVD) in diabetics and uses thereof |
Country Status (1)
Country | Link |
---|---|
CN (6) | CN116087485B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116087485B (en) * | 2021-11-08 | 2023-10-20 | 中国医学科学院阜外医院 | Biomarkers for early prediction of cardiovascular disease (CVD) in diabetics and uses thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3164204A1 (en) * | 2019-12-16 | 2021-06-24 | Hill's Pet Nutrition, Inc. | Methods, kits and compositions for diagnosing and treating renal disease |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014018851A1 (en) * | 2012-07-26 | 2014-01-30 | Joslin Diabetes Center, Inc. | Predicting and treating diabetic complications |
JP6404834B2 (en) * | 2013-01-31 | 2018-10-17 | メタボロン,インコーポレイテッド | Biomarkers associated with the progression of insulin resistance and methods of using the same |
JP6443937B2 (en) * | 2013-10-28 | 2018-12-26 | 株式会社サリバテック | Salivary biomarker for pancreatic cancer and method for distinguishing pancreatic cancer patient from healthy person using the same |
WO2017029401A1 (en) * | 2015-08-19 | 2017-02-23 | Metanomics Gmbh | Means and methods for diagnosing cardiac disease in a subject |
CA3018289A1 (en) * | 2016-05-24 | 2017-11-30 | Excision Biotherapeutics, Inc. | Metabalomics and viral diagnostics suite |
CN106544394A (en) * | 2016-12-09 | 2017-03-29 | 南京千年健干细胞基因工程有限公司 | Indicate mark, reagent and the kit of mescenchymal stem cell directed differentiation potential |
US20210364526A1 (en) * | 2018-05-23 | 2021-11-25 | The Regents Of The University Of California | Methods of selecting subjects for treatment with metabolomic modulators |
CN109298115B (en) * | 2018-10-19 | 2020-07-28 | 深圳市绘云生物科技有限公司 | Quantitative detection method for multiple metabolites in biological sample and metabolic chip |
CN110850074B (en) * | 2019-11-08 | 2023-04-11 | 郑州大学第一附属医院 | Screening method and application of liver cirrhosis anion marker |
CN112730638B (en) * | 2020-11-25 | 2022-07-29 | 首都医科大学附属北京朝阳医院 | Diabetes combined myocardial infarction metabolism marker, detection reagent and kit |
CN112505228B (en) * | 2021-01-04 | 2022-10-21 | 深圳市绘云生物科技有限公司 | Metabolic marker combination for assessing cardiovascular disease risk of subject and application thereof |
CN113447599B (en) * | 2021-08-27 | 2021-11-16 | 宝枫生物科技(北京)有限公司 | Biomarker for diagnosing cerebral infarction of patient with leukoencephalopathy and application of biomarker |
CN116087485B (en) * | 2021-11-08 | 2023-10-20 | 中国医学科学院阜外医院 | Biomarkers for early prediction of cardiovascular disease (CVD) in diabetics and uses thereof |
-
2021
- 2021-11-08 CN CN202211510543.9A patent/CN116087485B/en active Active
- 2021-11-08 CN CN202211510601.8A patent/CN116087487A/en active Pending
- 2021-11-08 CN CN202111315640.8A patent/CN114113573B/en active Active
- 2021-11-08 CN CN202211510557.0A patent/CN116087486B/en active Active
- 2021-11-08 CN CN202211513991.4A patent/CN116087489A/en active Pending
- 2021-11-08 CN CN202211510605.6A patent/CN116087488A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3164204A1 (en) * | 2019-12-16 | 2021-06-24 | Hill's Pet Nutrition, Inc. | Methods, kits and compositions for diagnosing and treating renal disease |
Non-Patent Citations (6)
Title |
---|
Circulating Palmitoyl Sphingomyelin Is Associated With Cardiovascular Disease in Individuals With Type 2 Diabetes: Findings From the China Da Qing Diabetes Study;Chen Yanyan et al.;Diabetes Care;第45卷(第3期);全文 * |
Lipidomic Profiling Identifies Signatures of Poor Cardiovascular Health;Irma Magaly Rivas Serna et al.;Metabolites;第11卷(第747期);1-15, SI * |
Sphingomyelin and progression of renal and coronary heart disease in individuals with type 1 diabetes;Drazenka Pongrac Barlovic et al.;Diabetologia;第63卷(第9期);1847-1856 * |
糖尿病相关心血管疾病的血浆代谢组学研究--大庆糖尿病预防研究随访研究;陈燕燕;邹忠梅;贾红梅;钱鑫;巩秋红;安雅莉;李光伟;中国循环杂志;第31卷(增刊);全文 * |
陈燕燕 ; 邹忠梅 ; 贾红梅 ; 钱鑫 ; 巩秋红 ; 安雅莉 ; 李光伟.糖尿病相关心血管疾病的血浆代谢组学研究--大庆糖尿病预防研究随访研究.2016中国心脏大会.2016,全文. * |
陈燕燕 ; 邹忠梅 ; 贾红梅 ; 钱鑫 ; 巩秋红 ; 安雅莉 ; 李光伟.糖尿病相关心血管疾病的血浆代谢组学研究--大庆糖尿病预防研究随访研究.中国循环杂志.2016,第31卷(第0z1期),全文. * |
Also Published As
Publication number | Publication date |
---|---|
CN116087485B (en) | 2023-10-20 |
CN116087488A (en) | 2023-05-09 |
CN116087485A (en) | 2023-05-09 |
CN114113573A (en) | 2022-03-01 |
CN116087489A (en) | 2023-05-09 |
CN116087486A (en) | 2023-05-09 |
CN114113573B (en) | 2022-11-11 |
CN116087487A (en) | 2023-05-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Daniluk et al. | Untargeted metabolomics and inflammatory markers profiling in children with Crohn’s disease and ulcerative colitis—A preliminary study | |
AU2017201455B2 (en) | Means and methods for diagnosing and monitoring heart failure in a subject | |
US20050101023A1 (en) | Methods for diagnosing urinary tract and prostatic disorders | |
CN108020592B (en) | The method and application of phosphatidyl choline in a kind of mass spectrometry quantitative analysis serum of Capillary Electrophoresis | |
CN113049696B (en) | Metabolite for diagnosing whether subject suffers from Alzheimer disease and application thereof | |
US20080261317A1 (en) | Methods of Detecting Myocardial Ischemia and Myocardial Infarction | |
Chen et al. | UHPLC/Q-TOFMS-based plasma metabolomics of polycystic ovary syndrome patients with and without insulin resistance | |
US8758992B2 (en) | Method for the differential diagnosis of non-alcoholic fatty liver disease based on a metabolomic profile | |
US20140148349A1 (en) | Metabolite Biomarkers for the Detection of Esophageal Cancer Using NMR | |
Yannell et al. | Multiple reaction monitoring (MRM)-profiling with biomarker identification by LC-QTOF to characterize coronary artery disease | |
CN112083111A (en) | Non-invasive diagnosis marker for chronic drug-induced liver injury related cirrhosis and application thereof | |
CN112305121B (en) | Application of metabolic marker in atherosclerotic cerebral infarction | |
CN116087486B (en) | Biomarkers for early prediction of cardiovascular disease (CVD) in diabetics and uses thereof | |
Liang et al. | Untargeted lipidomics study of coronary artery disease by FUPLC-Q-TOF-MS | |
CN112669958B (en) | Metabolites as biomarkers for disease diagnosis | |
CN115684451A (en) | Esophageal squamous carcinoma lymph node metastasis diagnosis marker based on metabonomics and application thereof | |
CN115112776B (en) | Combined marker, application thereof in diagnosing atrial fibrillation and diagnostic reagent or kit | |
WO2010018165A1 (en) | Method for the diagnosis of non-alcoholic steatohepatitis based on a metabolomic profile | |
WO2017186859A1 (en) | Method for lipid profiling in full blood | |
US20130037709A1 (en) | Method for Clinically Monitoring Niacin and Niacin Metabolites in Serum or Plasma | |
Koussiouris | Investigating Lipid Metabolites in the Serum of Psoriatic Arthritis Patients Using Solid Phase Microextraction–Liquid Chromatography–High-resolution Mass Spectrometry | |
WO2023010752A1 (en) | Marker, detection method, and kit for evaluating cardiac injury of schizophrenia patient | |
CN115266985B (en) | UHPLC-QTOF-MS-based laryngeal cancer patient serum lipidomic detection method | |
KULAKSIZOĞLU et al. | Measurement of methionine level with the LC-ESI-MS/MS method in schizophrenic patients | |
Tirelli et al. | Exploring the Potential Role of Metabolomics in COPD: A Concise Review |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |